Prete Fernando, Prete Francesco Paolo, Nitti Paolo, De Luca Raffaele, Vincenti Leonardo
Cattedra di Chirurgia Generale, Università degli Studi di Bari.
Chir Ital. 2007 Nov-Dec;59(6):763-70.
Certain aspects of the epidemiology, classification and therapy of adenocarcinoma of the anorectal junction (< 5 cm from the anal verge) are not well standardised to date. To evaluate the recent advances in the surgical management we reviewed our database, focusing on the oncological and functional results of intersphincteric resection. From 1989 to 2005 we treated 183 adenocarcinomas of the anorectal junction with a curative intent by 106 total proctetomies (84 of which by intersphinteric resection), 54 abdominoperineal resections, 22 transanal local excision and 1 Hartmann procedure. Intersphincteric resections were performed in 51 males and 33 females, mean age 62, with the following clinical stages: 28 stage 1, 55 stages II and III, 1 stage IV; radiotherapy was administered preoperatively to 27 patients and postoperatively to 18. Fifty-five intersphinteric resections were performed by open surgery and 29 by laparoscopy (since 2001). All the procedures were R0 except for 2 R1 (readily converted to abdominoperineal resections). Perioperative mortality (30 days) was 1.1% and the overall morbidity was 27.7% (including a 6% leakage rate). Assessment of anal sphincter function recovery one year after restoration of bowel continuity showed good continence in 76% of the patients; 2 patients have a permanent ostomy. After an average 60-month follow-up (min. 30 months) the local recurrence rate was 2.4% and the actuarial 5-year survival rate 81.7%. Our experience shows a drop in abdominoperineal resections in the last 5 years from 56.5% to 17.8%, while the intersphincteric resection rate has increased from 32.6% to 66%. The oncological results of intersphincteric resection compare favourably with those of abdominoperineal resection and functional recovery appears satisfactory.
迄今为止,肛管直肠交界腺癌(距肛缘<5cm)的某些流行病学、分类及治疗方面尚未得到很好的标准化。为评估手术治疗的最新进展,我们回顾了我们的数据库,重点关注括约肌间切除术的肿瘤学及功能结果。1989年至2005年,我们对183例肛管直肠交界腺癌患者进行了根治性治疗,其中106例行全直肠切除术(84例为括约肌间切除术),54例行腹会阴联合切除术,22例行经肛门局部切除术,1例行Hartmann手术。51例男性和33例女性接受了括约肌间切除术,平均年龄62岁,临床分期如下:28例为I期,55例为II期和III期,1例为IV期;27例患者术前接受放疗,18例术后接受放疗。55例括约肌间切除术通过开放手术进行,29例通过腹腔镜手术进行(自2001年起)。除2例R1切除(随后很容易转为腹会阴联合切除术)外,所有手术均为R0切除。围手术期死亡率(30天)为1.1%,总体发病率为27.7%(包括6%的渗漏率)。肠道连续性恢复一年后对肛门括约肌功能恢复的评估显示,76%的患者控便良好;2例患者有永久性造口。经过平均60个月的随访(最短30个月),局部复发率为2.4%,5年精算生存率为81.7%。我们的经验表明,在过去5年中,腹会阴联合切除术的比例从56.5%降至17.8%,而括约肌间切除术的比例从32.6%增至66%。括约肌间切除术的肿瘤学结果优于腹会阴联合切除术,且功能恢复似乎令人满意。